SEC Form 4 · accession 0001179110-15-002986
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Norbert W Bischofberger
Officer — EVP, R&D and CSO
Period of report
Feb 17, 2015
Accepted (ET)
Feb 19, 2015 · 6:42 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 17, 2015 | M | 70,000 | $16.395 | A | 235,168 | D | |
| Common StockF3 | Feb 17, 2015 | S | 29,114 | $102.6548 | D | 206,054 | D | |
| Common StockF4 | Feb 17, 2015 | S | 40,886 | $103.2639 | D | 165,168 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F2 | $16.395 | Feb 17, 2015 | M | 70,000 | D | — | Jan 22, 2017 | Common Stock | 70,000 | 20,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $101.98 to $102.97. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $102.98 to $103.62. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request